Skip to main content

Cancer Biology

Edited by:
Gerry Melino, MD, PhD, University of Rome "Tor Vergata", Italy
Valentina Tassinari, PhD, University of Rome "Tor Vergata", Italy

Submission Status: Closed   |   Submission Deadline: 31 March 2024

This collection is no longer accepting submissions.

Biology Direct is calling for submissions to our new Collection on Cancer Biology. This Collection supports and amplifies research related to SDG 3, Good Health and Well-Being.

Image credit: Michael / Generated with AI /

About the collection

The identification of genes related to cancer origin and progression has been greatly expanded with the establishment of The Cancer Genome Atlas (TCGA) and of the Pan-Cancer Analysis of Whole Genomes (PCAWG) consortia, which include most tumor types, matching DNA sequencing, and RNA transcripts. As a result, we now have a better grasp of the molecular pathways underlying cancer, its biochemistry, and, therefore, new therapeutic targets.

In this Collection, we aim to showcase scientific papers which describe distinct aspects of the molecular mechanisms involved in cancer development and progression, as well as its liaison with new potential therapeutic interventions. We describe distinct aspects of precision oncology, the ability to stratify patients with distinct prognostic features and therapeutic requirements, as well as its liaison with the current complexity of the underlying molecular mechanisms.

  1. Long noncoding RNAs (lncRNAs) are implicated in the initiation and progression of diffuse large B-cell lymphoma (DLBCL). Small nucleolar RNA host gene 20 (SNHG20) has been recognized as a critical lncRNA in mu...

    Authors: Chaoyu Wang, Wen Fu, Youju Zhang, Xiaoge Hu, Qiuran Xu and Xiangmin Tong
    Citation: Biology Direct 2024 19:47
  2. Triple-negative breast cancer (TNBC) is more aggressive and has a higher metastasis rate compared with other subtypes of breast cancer. Due to the lack of drug-targetable receptors, chemotherapy is now the onl...

    Authors: Yuxiang Lin, Yan Li, Xiaobin Chen, Xuan Jin, Meichen Jiang, Han Xiao, Lili Chen, Minyan Chen, Wenzhe Zhang, Hanxi Chen, Qian Nie, Rongrong Guo, Wenhui Guo, Fangmeng Fu and Chuan Wang
    Citation: Biology Direct 2024 19:42
  3. Epidermal growth factor receptor (EGFR)-targeted therapy is an important treatment for RAS wild-type metastatic colorectal cancer (mCRC), but the resistance mechanism remains unclear. Here, the differential ex...

    Authors: Yiting Geng, Xiao Zheng, Dachuan Zhang, Shanshan Wei, Jun Feng, Wei Wang, Luo Zhang, Changping Wu and Wenwei Hu
    Citation: Biology Direct 2024 19:36
  4. LncRNA PCED1B-AS1 is abnormally expressed in multiple cancers and has been confirmed as an oncogene. Our study aimed to investigate the regulatory mechanism of lncRNA PCED1B-AS1 in gastric cancer.

    Authors: Jia Cao, Yicheng Yang, Bensong Duan, Haibin Zhang, Qinwei Xu, Junyi Han and Bing Lu
    Citation: Biology Direct 2024 19:34
  5. Deubiquitinating enzymes (DUBs) cleave ubiquitin on substrate molecules to maintain protein stability. DUBs reportedly participate in the tumorigenesis and tumour progression of hepatocellular carcinoma (HCC)....

    Authors: Yingnan Yang, Siying Jia, Ning Zhu, Xuelian Xiao, Ying Ma, Kangsheng Tu, Yong Guo and Qiuran Xu
    Citation: Biology Direct 2024 19:31
  6. Circular RNAs (circRNAs) are a class of highly multifunctional single-stranded RNAs that play crucial roles in cancer progression, including osteosarcoma (OS). Circ_0002669, generated from the dedicator of cyt...

    Authors: Ying Zhang, Yizhou Zhan, Zhaoyong Liu, Huancheng Guo, Dongchen Liu and Chuangzhen Chen
    Citation: Biology Direct 2024 19:25
  7. Mammalian enabled (MENA) protein is a member of the enabled/vasodilator stimulated phosphoprotein (Ena/VASP) protein family, which regulates cytoplasmic actin network assembly. It plays a significant role in b...

    Authors: Lifang He, Chuanghong She, Sen Jiang, Zhaochang Qi, Zihao Deng, Likeng Ji, Yukun Cui and Jundong Wu
    Citation: Biology Direct 2024 19:21
  8. The outcome of Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) remain dismal despite the development of treatment. Targeted therapy is gaining more and more attention in improving prognosis.

    Authors: Qiao Zhou, Jiamin Zhang, Jingsong Zhang, Simin Liang, Duo Cai, Han Xiao, Yu Zhu, Wenqiong Xiang, Fernando Rodrigues-Lima, Jianxiang Chi, Fabien Guidez and Li Wang
    Citation: Biology Direct 2024 19:6
  9. The uc.291 transcript controls keratinocytes differentiation by physical interaction with ACTL6A and subsequent induction of transcription of the genes belonging to the epidermal differentiation complex (EDC)....

    Authors: Mara Mancini, Simone Sergio, Angela Cappello, Timea Farkas, Francesca Bernassola, Claudia Scarponi, Cristina Albanesi, Gerry Melino and Eleonora Candi
    Citation: Biology Direct 2023 18:82
  10. Cancer immunotherapy, alone or in combination with conventional therapies, has revolutionized the landscape of antineoplastic treatments, with dendritic cells (DC) emerging as key orchestrators of anti-tumor i...

    Authors: Peng Liu, Liwei Zhao, Guido Kroemer and Oliver Kepp
    Citation: Biology Direct 2023 18:71

Submission Guidelines

Back to top

This Collection welcomes submission of original Research Articles and Reviews. 

Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Cancer Biology" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.